Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape.

Metabolic reprogramming plays an important role in cancer development and progression and is a well-established hallmark of cancer. Despite its inherent complexity, cellular metabolism can be decomposed into functional modules that represent fundamental metabolic processes. Here, we performed a pan-cancer study involving 9,428 samples from 25 cancer types to reveal metabolic modules whose individual or coordinated activity predict cancer type and outcome, in turn highlighting novel therapeutic opportunities. Integration of gene expression levels into metabolic modules suggests that the activity of specific modules differs between cancers and the corresponding tissues of origin. Some modules may cooperate, as indicated by the positive correlation of their activity across a range of tumors. The activity of many metabolic modules was significantly associated with prognosis at a stronger magnitude than any of their constituent genes. Thus, modules may be classified as tumor suppressors and oncomodules according to their potential impact on cancer progression. Using this modeling framework, we also propose novel potential therapeutic targets that constitute alternative ways of treating cancer by inhibiting their reprogrammed metabolism. Collectively, this study provides an extensive resource of predicted cancer metabolic profiles and dependencies.Significance: Combining gene expression with metabolic modules identifies molecular mechanisms of cancer undetected on an individual gene level and allows discovery of new potential therapeutic targets. Cancer Res; 78(21); 6059-72. ©2018 AACR.

[1]  O. Maddocks,et al.  One-carbon metabolism in cancer , 2017, British Journal of Cancer.

[2]  Anne Richelle,et al.  A Systematic Evaluation of Methods for Tailoring Genome-Scale Metabolic Models. , 2017, Cell systems.

[3]  L. Cantley,et al.  PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. , 2017, Cancer discovery.

[4]  Francisco Salavert,et al.  High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes , 2016, bioRxiv.

[5]  H. Rehrauer,et al.  Prognostic value of cross-omics screening for kidney clear cell renal cancer survival , 2016, Biology Direct.

[6]  J. Settleman,et al.  Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis. , 2016, Cell metabolism.

[7]  Wei Jiang,et al.  Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway , 2016, Scientific Reports.

[8]  Francisco Salavert,et al.  Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models , 2016, Nucleic Acids Res..

[9]  G. Robertson,et al.  The Role of Cholesterol in Cancer. , 2016, Cancer research.

[10]  J. Blenis,et al.  Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers , 2016, Proceedings of the National Academy of Sciences.

[11]  Walter Kolch,et al.  Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients , 2015, Science Signaling.

[12]  Francisco Salavert,et al.  Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity , 2015, Scientific Reports.

[13]  S. Sarkar,et al.  Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation , 2015, Cancer cell.

[14]  R. Medeiros,et al.  Antiproliferative effects of β-blockers on human colorectal cancer cells. , 2015, Oncology reports.

[15]  Rosa D. Hernansaiz-Ballesteros,et al.  Assessing the impact of mutations found in next generation sequencing data over human signaling pathways , 2015, Nucleic Acids Res..

[16]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[17]  T. Ahern,et al.  Statins and breast cancer prognosis: evidence and opportunities. , 2014, The Lancet. Oncology.

[18]  N. Hay,et al.  The pentose phosphate pathway and cancer. , 2014, Trends in biochemical sciences.

[19]  R. Weinberg,et al.  Dihydropyrimidine Accumulation Is Required for the Epithelial-Mesenchymal Transition , 2014, Cell.

[20]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[21]  I. Amelio,et al.  Serine and glycine metabolism in cancer☆ , 2014, Trends in biochemical sciences.

[22]  J. Dopazo Genomics and transcriptomics in drug discovery. , 2014, Drug discovery today.

[23]  Zachary A. King,et al.  Constraint-based models predict metabolic and associated cellular functions , 2014, Nature Reviews Genetics.

[24]  M. Gleave,et al.  Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. , 2013, Journal of the National Cancer Institute.

[25]  Francisco Salavert,et al.  Inferring the functional effect of gene expression changes in signaling pathways , 2013, Nucleic Acids Res..

[26]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[27]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[28]  D. Vitkup,et al.  Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.

[29]  Susumu Goto,et al.  Modular Architecture of Metabolic Pathways Revealed by Conserved Sequences of Reactions , 2013, J. Chem. Inf. Model..

[30]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[31]  Neil Swainston,et al.  Improving metabolic flux predictions using absolute gene expression data , 2012, BMC Systems Biology.

[32]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[33]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[34]  Carlos González-Alcón,et al.  Modeling of leishmaniasis infection dynamics: novel application to the design of effective therapies , 2012, BMC Systems Biology.

[35]  Jason A. Papin,et al.  TIGER: Toolbox for integrating genome-scale metabolic models, expression data, and transcriptional regulatory networks , 2011, BMC Systems Biology.

[36]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular Systems Biology.

[37]  S. Gruber,et al.  Use of bisphosphonates and reduced risk of colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. V. Vander Heiden Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.

[39]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[40]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[41]  M. Ehrlich DNA hypomethylation in cancer cells. , 2009, Epigenomics.

[42]  J. Dopazo,et al.  Gene set internal coherence in the context of functional profiling , 2009, BMC Genomics.

[43]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[44]  O. Fadare,et al.  Clinical and pathologic aspects of basal-like breast cancers , 2008, Nature Clinical Practice Oncology.

[45]  Ralph J Deberardinis,et al.  Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.

[46]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[47]  S. Sukumar,et al.  Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells* , 2006, Journal of Biological Chemistry.

[48]  S. Curley,et al.  Incidence and distribution of argininosuccinate synthetase deficiency in human cancers , 2004, Cancer.

[49]  Zachary Shriver,et al.  Roles of heparan-sulphate glycosaminoglycans in cancer , 2002, Nature Reviews Cancer.

[50]  R. Coleman Management of bone metastases. , 1995, The oncologist.

[51]  E. Gerner,et al.  Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. , 1998, Nutrition and cancer.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  S. Hakomori Glycosphingolipids as differentiation-dependent, tumor-associated markers and as regulators of cell proliferation , 1984 .

[54]  O. Warburg,et al.  The Metabolism of Carcinoma Cells , 1925 .

[55]  D.,et al.  Regression Models and Life-Tables , 2022 .